These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30783954)

  • 41. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.
    Amin AM; Sheau Chin L; Teh CH; Mostafa H; Mohamed Noor DA; Abdul Kader MASK; Kah Hay Y; Ibrahim B
    Eur J Pharm Sci; 2018 May; 117():351-361. PubMed ID: 29526765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.
    Ahn SG; Lee SH; Yoon JH; Kim WT; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Yoon J; Choe KH
    JACC Cardiovasc Interv; 2012 Mar; 5(3):259-67. PubMed ID: 22440490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
    Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
    Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
    Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aspirin-Free Strategies After Complex PCI: Type of P2Y
    Gragnano F; Calabrò P
    JACC Cardiovasc Interv; 2024 May; 17(9):1131-1133. PubMed ID: 38749593
    [No Abstract]   [Full Text] [Related]  

  • 57. Ticagrelor in Clopidogrel-Treated Patients With Chronic Coronary Syndrome Undergoing PCI: Translating Pharmacodynamic Into Clinical Evidence.
    Laudani C; Angiolillo DJ
    JACC Cardiovasc Interv; 2024 Jun; 17(12):1422-1424. PubMed ID: 38842998
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
    Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
    Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.
    Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
    Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.